Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 21,489 matching trials from the live ClinicalTrials.gov search.

Filters: Boston, Massachusetts Clear all

Conditions: Depressive Symptoms, Anxiety
Interventions: Expressive Writing on Minority Stressors, Neutral Writing; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Nasal Polyps
Interventions: Placebo (for dupilumab), Dupilumab, Mometasone furoate nasal spray; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Rolling Hills Estates, California • Denver, Colorado • Boston, Massachusetts + 2 more

Conditions: Diabetes, Physical Activity
Interventions: Group Walk, Individual Walk; Behavioral
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain, Ankle Injuries
Interventions: Not listed
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Angioedema, Hereditary, Types I and II
Interventions: KVD824, Placebo to KVD824; Drug
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 10 more

Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
Interventions: AG-120, Placebo, Azacitidine; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Louisville, Kentucky • Boston, Massachusetts

Conditions: Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash, Non-Steroid Containing Mouthwash; Drug · Other
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more

Conditions: Irritable Bowel Syndrome
Interventions: TRYP-0082, Psychotherapy; Drug · Behavioral
Lead sponsor: TRYP Therapeutics; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Premature Ventricular Contractions, Congestive Heart Failure
Interventions: PVC ablation; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: ofatumumab, ibrutinib; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 25
States / cities: La Jolla, California • Los Angeles, California • Santa Maria, California + 20 more

Conditions: High Risk Newly Diagnosed Multiple Myeloma
Interventions: Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant; Drug
Lead sponsor: Multiple Myeloma Research Consortium; Network
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 12
States / cities: Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Migraine Disorders
Interventions: Placebo, Combination Product (sumatriptan succinate/naproxen sodium); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 28
States / cities: Jasper, Alabama • Oceanside, California • San Francisco, California + 25 more

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Itacitinib, Placebo, Prednisone, Methylprednisolone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 49
States / cities: La Jolla, California • Los Angeles, California • Stanford, California + 38 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions: Ramelteon, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cystic Fibrosis
Interventions: Throat Swab; Procedure
Lead sponsor: Tufts Medical Center; Other
Eligibility: 1 Day to 3 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma
Interventions: Afamitresgene autoleucel; Genetic
Lead sponsor: USWM CT, LLC; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2038
U.S. locations: 10
States / cities: Palo Alto, California • Bethesda, Maryland • Boston, Massachusetts + 7 more

Conditions: Cytomegalovirus Infections
Interventions: Letermovir; Drug
Lead sponsor: Amy C. Sherman, MD; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Ischemic Stroke
Interventions: intracranial angioplasty and stenting, intensive medical management; Device · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 30 Years to 80 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Glendale, California + 38 more

Conditions: Lung Cancer
Interventions: carboplatin, chemotherapy, paclitaxel, radiation therapy; Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 47
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more

Conditions: Neoplasms
Interventions: Dostarlimab; Biological
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 48
States / cities: Birmingham, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 38 more

Conditions: Lactation
Interventions: Recombinant human prolactin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amputation
Interventions: e-OPRA Implant System for Transtibial Amputees; Device
Lead sponsor: Massachusetts Institute of Technology; Other
Eligibility: 22 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Breast Cancer
Interventions: cisplatin, bevacizumab, doxorubicin, cyclophosphamide, paclitaxel; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Peripheral Arterial Disease (PAD)
Interventions: WIRION; Device
Lead sponsor: Gardia Medical; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Denver, Colorado • Davenport, Iowa • New Orleans, Louisiana + 5 more

Search by objective public record fields.

Expressive Writing on Minority Stressors Among Sexual Minority Veterans

An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis

Adopting a Physically Active Lifestyle Through Organized Walk Events Among Joslin Clinic Patients

Associated Joint Pain With Controlled Ankle Movement (CAM) Walker Boot Wear

A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

Early Elimination of Premature Ventricular Contractions in Heart Failure

A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Horizon Two: HR NDMM (MMRC-100)

A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)

GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease

Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia

Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of Life

SPEARHEAD-3 Pediatric Study

Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection

Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis

Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Recombinant Human Prolactin for Lactation Induction

Osseointegrated Transtibial Prosthesis With Neural Interface

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

Evaluation of WIRION™ EPS in Lower Extremities Arteries